Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Peking University Cancer Hospital & Institute
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07357532CT.gov Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | — | Not Yet Recruiting | — | — | — |
NCT07106528CT.gov Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06786312CT.gov A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06749691CT.gov Liposomal Irinotecan and Apatinib in ES-SCLC | — | Recruiting | — | — | — |
NCT06773156CT.gov Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer | — | Enrolling By Invitation | — | — | — |
NCT06480864CT.gov Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06429696CT.gov PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06483282CT.gov A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06475209CT.gov Adebrelimab + Apatinib in SCLC Maintenance Therapy | — | Recruiting | — | — | — |
NCT04901754CT.gov Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer | — | Unknown | — | — | — |
Show 15 more trialsShow fewer
NCT04683198CT.gov Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC | — | Unknown | — | — | — |
NCT05001412CT.gov Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC | — | Unknown | — | — | — |
NCT04490421CT.gov Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. | — | Unknown | — | — | — |
NCT04659785CT.gov A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | — | Unknown | — | — | — |
NCT04453930CT.gov A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | — | Unknown | — | — | — |
NCT04128800CT.gov Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03651219CT.gov Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03547804CT.gov A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03417895CT.gov SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy | — | Completed | — | — | — |
NCT03389087CT.gov Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02980809CT.gov Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | — | Unknown | — | — | — |
NCT03135977CT.gov Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy | — | Unknown | — | — | — |
NCT02995187CT.gov Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) | — | Unknown | — | — | — |
NCT02945852CT.gov Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | — | Completed | — | — | — |
NCT02875457CT.gov Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivoceranib (this asset) | Peking University Cancer Hospital & Institute | P3 | B · 63 |
| Benmelstobart | Yayi He | P4 | A |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Irinotecan | Sichuan University | P4 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Rivoceranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Cancer | — | P4 | BBB · 73 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 72 |
| Cancer | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivoceranib in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivoceranib-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →